Lasofoxifene and cardiovascular events in postmenopausal women with osteoporosis: Five-year results from the Postmenopausal Evaluation and Risk Reduction with Lasofoxifene (PEARL) trial.

Publication Type:

Journal Article


Circulation, Volume 122, Issue 17, p.1716-24 (2010)


2010, Aged, Aged, 80 and over, Breast Neoplasms, Center-Authored Paper, Coronary Disease, Dose-Response Relationship, Drug, Double-Blind Method, Endpoint Determination, Female, Follow-Up Studies, Fractures, Bone, Humans, Incidence, Longitudinal Studies, Middle Aged, Osteoporosis, Postmenopausal, Public Health Sciences Division, Pyrrolidines, Receptors, Estrogen, Risk Factors, Stroke, Tetrahydronaphthalenes, Treatment Outcome


In the Postmenopausal Evaluation and Risk Reduction With Lasofoxifene (PEARL) trial, women assigned to lasofoxifene 0.5 mg/d had a lower risk of major coronary heart disease (CHD) events and stroke, whereas women assigned to lasofoxifene 0.25 mg/d had a lower risk of stroke. Both doses of lasofoxifene increased the risk of venous thromboembolic events. In this report, we provide comprehensive cardiovascular end-point data, including component events comprising the composite end point of major CHD events, and evaluate whether the effect of lasofoxifene 0.5 mg/d is consistent across different categories of CHD risk.